Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1699968

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of medication costs on community pharmacies.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20988
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20979 question first answered 19/04/2024 09:54:36 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699971

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to develop a Priority Review programme for medical devices.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20991
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20992 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699972

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment: Reviews
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 23 June 2023 to Question 189729 on Medicines and Healthcare products Regulatory Agency, whether she plans to initiate a priority review for medical devices.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20992
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699973

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether (a) the Medicines and Healthcare products Regulatory Agency and (b) NICE will prioritise the regulatory timelines for medical devices that (i) respond to conditions outlined in the Major Conditions Strategy and (ii) where there is unmet need.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20993
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20992 question first answered 22/04/2024 11:22:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1700007

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of the medication reimbursement mechanism for community pharmacists.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	20979
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20988 question first answered 19/04/2024 09:54:35 answering member 4044 label Biography information for Andrew Stephenson
tabling member	3973 label Biography information for Grahame Morris

1700026

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the annual cost to the NHS of the use of illegal drugs.
tabling member constituency	Hayes and Harlington
tabling member printed	John McDonnell
uin	20843
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Dame Carol Black’s review of evidence related to drugs, published in February 2020, estimated the cost to the National Health Service of illegal drug use at £431 million per annum. This includes admissions in secondary care, prison treatment and infectious disease. However, this figure does not include other NHS costs such as primary care or accident and emergency usage so will be an underestimate.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 22/04/2024 16:22:19 answering member 4117 label Biography information for Andrea Leadsom
tabling member	178 label Biography information for John McDonnell

1700038

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Private Sector
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much was spent on private sector contracts for the provision of clinical services in the most recent financial year for which data is available.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	20901
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20902 question first answered 24/05/2024 13:17:27 answering member 4044 label Biography information for Andrew Stephenson
tabling member	481 label Biography information for Sir George Howarth

1700047

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Alzheimer's Disease: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she has taken to support research and development of the ACI-24 Alzheimer’s disease treatment.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	20911
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). The Government is strongly committed to supporting research into dementia, including Alzheimer’s disease treatment, and has committed to doubling funding for dementia research to £160 million per year, by the end of 2024/25.</p><p> </p><p>In addition, the NIHR’s infrastructure provides funding for clinical expertise, specialist facilities, the workforce, and support services, which underpin research across a range of clinical areas, including Alzheimer’s disease treatments. Specifically, the NIHR’s Oxford Health Clinical Research Facility (CRF) has enabled the delivery of the ABATE part 1 trial, which seeks to study the effects of the ACI-24 vaccine in those diagnosed with early-stage Alzheimer’s disease. The NIHR’s CRFs are purpose-built facilities for early-phase, experimental medicine, and supporting life science companies throughout the research process from study, design, data collection, and trial management.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:07:46 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1447 label Biography information for Andrew Rosindell

1700048

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer and Dementia: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how much funding was provided for (a) dementia and (b) cancer research in the 2022-23 financial year.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	20912
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>Government responsibility for delivering dementia research and dementia research funding is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science Innovation and Technology, with research delivered via UK Research and Innovation.</p><p>In 2022/23, we estimate that total Government spend on dementia research was £99.9 million, with £35.1 million of this being via the NIHR. The Department of Health and Social Care spends £1.3 billion per year on health research through the NIHR. NIHR research expenditure for all cancers was £121.8 million in 2022/23, and the NIHR spends more on cancer than any other disease group.</p><p>The NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. The NIHR welcomes funding applications for research into any aspect of human health, including all cancers and dementia types. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 16:07:17 answering member 4044 label Biography information for Andrew Stephenson
tabling member	1447 label Biography information for Andrew Rosindell

1700067

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Private Sector
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the value of contracts awarded to non-NHS providers was for the provision of clinical services in the (a) 2022-23, (b) 2021-22 and (c) 2020-21 financial years.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	20902
answer	answer is ministerial correction date of answer 24/05/2024 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20901 question first answered 24/05/2024 13:17:27 answering member 4044 label Biography information for Andrew Stephenson
tabling member	481 label Biography information for Sir George Howarth